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1 Liver Transplantation 
Thomas E. Starzl, M.D., Ph.D. 
The concept of liver transplantation is a relatively recent one. 
The first descriptions of liver replacement in experimental animals 
were published less than 2S years ago (1,2), and the first attempt at 
clinical liver transplantation was not made until March I, 1963 (3). 
In spite of continued efforts for the next 17 years, the great 
avalanche of human liver transplantations worldwide did not begin 
until 1980, only five years ago. A number of factors contributed to 
the growing interest in and success with orthotopic liver trans-
plantation. Of these, the most important by far was the introduction 
of the new immunosuppressive agent, cyclosporine. In many of 
the contributions in this book, the influence of this drug will be 
described. Other topics to be considered will be an increased 
understanding of the anesthetic and intensive-care management 
of these patients, tissue matching, improvements in surgical tech-
niques, and advances in organ procurement and preservation. My 
notations on some of these subjects will be superficial, but the 
topics will be fully developed by other authors. 
IMMUNOSUPPRESSION 
Truly long survival after liver transplantation between outbred 
mongrel dogs was achieved more than 20 years ago using azathioprine 
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(4,5). One dog from that original study lived for more than 10 
years. 
The first extended survival of a human liver recipient was 
accomplished in the summer of 1967 (5), and the longest survival 
of any patient in the world today is now more than 15 years. This 
recipient, whose original disease was biliary atresia with an inci-
dental hepatoma, was treated with azathioprine, prednisone, and 
antilymphocyte globulin (ALG). 
Most of our liver recipients from 1963 through 1979 had this 
so-called triple-drug immunosuppression with azathioprine, pred-
nisone, and ALG. In some patients, cyclophosphamide was substi-
tuted for azathioprine, and in a few others, lymphoid depletion 
was achieved with thoracic duct drainage instead of ALG. Details 
of these variations are summarized else.where (6). The failure of 
any of the variations to influence the survival after liver trans-
plantation is evident from Figure 1.1. In the first trials from 1963 
to 1976, only about one-third of the patients lived for as long as 1 
year. In a smaller, second series of 30 patients treated from 1976 to 
1978, the I-year survival rose to 50%, but this improvement could 
not be sustained in the next 29 cases (Figure 1.1). 
In 1976, Borel et aI. (7) reported studies in rodents of a new 
immunosuppressive agent called cyclosporin A, and in late 1979, 
CaIne and his associates (8) reported the first major clinical expe-
rience with this drug. On the basis of their experience they 
recommended that the drug be used alone for transplantation of 
the kidney, liver, or pancreas. However, it was immediately obvious 
in our first trials with cyclosporine in late 1979 that the full 
exploitation of the drug would not be possible without combining 
it with other agents, of which prednisone was the most important 
(9). By so doing in kidney recipients, it was possible to minimize 
the contribution of homograft rejection to poor renal function, 
and at the same time to ameliorate the drug's nephrotoxicity by 
reducing the requisite doses of cyclosporine. Since then, other 
drugs have been proposed and/or tried in modifications of the 
"pharmacologic cocktail" concept, but the cyclosporine-steroid 
combination remains the benchmark. The dose-limiting factor of 
cyclosporine has almost always been nephrotoxicity. 
It is not hard to envision cyclosporine-steroid therapy as the 
modern analog of the original double-drug therapy with azathio-
prine and steroids. As a further analogy, the next logical step may 
.i 
I j 
j 
-J 
f 
I 
r lived for more than 10 
Jman liver recipient was 
, and the longest survival 
more than 15 years. This 
liary atresia with an inci-
nioprine, prednisone, and 
.63 through 1979 had this 
n with azathioprine, pred-
>phosphamide was substi-
hers, lymphoid depletion 
~e instead of ALe. Details 
~where (6). The failure of 
survival after liver trans-
t the first trials from 1963 
:ients lived for as long as 1 
:ients treated from 1976 to 
ut this improvement could 
:igure 1.1). 
tudies in rodents of a new 
;porin A, and in late 1979, 
Ie first major clinical expe-
of their experience they 
one for transplantation of 
it was immediately obvious 
in late 1979 that the full 
,ossible without combining 
ne was the most important 
t was possible to minimize 
on to poor renal function, 
e drug's nephrotoxicity by 
sporine. Since then, other 
ed in modifications of the 
.t the cyclosporine-steroid 
The dose-limiting factor of 
tephrotoxicity. 
,rine-steroid therapy as the 
drug therapy with azathio-
;y, the next logical step may 
I 
f 
i 
Li[ltT Trllnspilm/tl/ion / S 
PERCENT SURVlV AL 
IOOltlrl-------------------., Serin I (11183-111711) 
110 
80 
40 
20 
o~~--~~--~--~~--~~~~-~~ 
o 6 12 III 24 30 36 42 48 S4 60 
MONTHS 
N"' III 
-+-
Serie.2 (111711-111711) 
N '" 30 
~ 
Serie. 3 (11I711-1i711) 
N = 28 
-e--
FIGURE 1.1. Results obtained over a 16-year period (1963-1979) using 
the conventional immunosuppression. Note the failure to improve the 
results despite the acquisition of considerable experience. 
be the development of new "triple-drug" programs analogous to 
azathioprine, prednisone, and ALG but with cyclosporine-steroids 
being the baseline therapy to which one of the monoclonal ALG 
preparations that are undergoing preliminary clinical trials may be 
added. 
Our present opinion is that monoclonal ALG such as that 
developed by Cosimi and his associates (10) should be used to 
"rescue" patients in whom rejection cannot be controlled with 
cyclosporine-steroid therapy or in whom ther~ are severe limita-
tions for one reason or another to the amounts of cyclosporine 
that can be safely given. Such limitations to cyclosporine dosage, 
which are almost imposed by the drug's nephrotoxicity, are par-
ticularly important in applying knowledge about immunosuppres-
sion to the transplantation of extrarenal organs such as the heart 
and liver, since secondary renal failure is common in pa tients with 
cardiac and hepatic disease. This complicates the use of the cyclo-
sporine and completes a vicious cycle. 
We have used OKT3 monoclonal antibody therapy in a number 
of our kidney and liver reCipients. If rejection has developed despite 
cyclosporine-steroid therapy, reversal with OKT3 antibody usually 
has been striking. With the first dose of the monoclonal ALG, the 
circulating T-Iymphocytes are practically eliminated. Recurrence 
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of rejection after the monoclonal antibody course has been com-
pleted has been far less common using baseline therapy with 
cyclosporine-steroids than previously reported with azathioprine-
prednisone maintenance. 
In 1980, cyclosporine and prednisone were used to treat 12 
patients undergoing liver replacement. Two other liver recipients 
died on the operating table, for a total patient pool in that year of 
14, of whom 11 (78%) lived out the first year. If one counted only 
those who actually survived the operation to be able to receive 
drug therapy, the success rate was 11 of 12 (91.7%). 
These improved results became known in 1981 (6) and almost 
immediately a remarkable effect was seen on the case numbers. 
Increments occurred year-by-year, until in calendar year 1984 a 
total of 166 orthotopic liver transplaptations were performed at 
the University of Pittsburgh. Augmented activity in other centers 
throughout the world has been documented elsewhere (11). 
In our early trials of cyclosporine-steroid therapy, clinical 
judgment in managing the patients reflected a deliberate effort to 
balance the control of rejection against control of nephrotoxicity. 
Serum creatinine or BUN measures were used to guide the cyclo-
sporine doses, using low-grade nephrotoxicity to set limits. When 
techniques became available for assessment of whole blood or 
plasma cyclosporine concentration using radioimmunoassay (RIA) 
or high-performance liquid chromatography (HPLC), it became 
popular to rely heavily on the results of these tests for management 
decisions. Recipients of liver transplantation have benefited from 
this practice since intestinal absorption of cyclosporine after liver 
transplantation has been unpredictable. To assure adequate cy-
closporine blood concentrations, it frequently has been necessary 
to administer the drug both intravenously and by mouth for 
several days, weeks, or even months postoperatively. As absorption 
improves with the oral route, the intravenous doses are slowly 
reduced. 
However, blind faith in the cyclosporine blood levels cannot 
be used to replace good clinical judgment since toxicity of the drug, 
including that affecting the liver as well as the kidney, does not 
have an absolute correlation with the blood level. 
From 1963 through 1979, 170 patients were treated with 
conventional immunosuppression. The chances of living for a year 
after liver transplantation were only about 1 in 3 (Figure 1.2). 
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FIGURE 1.2. Marked improvement in results of liver transplantation 
after the introduction of cyclosporine-steriod th·erapy in early 1980. 
Subsequently, 244 liver recipients were provided with cyclosporine-
steroid therapy between March 1980 and July 1, 1984, allowing 
follow-ups (calculated in May 1985) of 10 months to more than 5 
years. The chances of I-year survival were more than d~uble~K 
Actuarial projections beyond 1 year indicate that these gams WIll 
be sustained for at least half a decade (Figure 1.2). 
THE ROLE Of TISSUE TYPING 
In patients treated ~ith cyclosporine-steroids after renal 
transplantation, the antigen matching at the A, B, or D loci has had 
little ~nfluence on the results. Such matching has not even been 
attempted for liver recipients. It is unlikely that this kind of tissue 
matching will playa significant role in further developments in 
liver transplantation. 
A surprising finding has been the remarkable resistance of the 
liver to hyperacute rejection (6). There has been no obvious penalty 
with transplantation of livers to recipients whose sera contain the 
cytotoxic antigraft antibodies that almost invariably lead to imme-
diate loss of kidney grafts. Furthermore, many liver transplanta-
tions have been and are being carried out across the ABO blood-group 
barriers that frequently (although not invariably) cause hyperacute 
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rejection of kidneys as the consequence of antigraft isoagglutinins. 
These observations have simplified some of the logistical problems 
of liver transplantation by highlighting the nonrelevance of typing 
and matching with this organ. 
IMPROVEMENTS IN TECHNIQUE 
The technical principles of liver transplantation have been 
well worked out for almost two decades, but two highly significant 
developments have occurred in the last few years. These are 
perfection of pump-driven veno-venous bypasses and the stan-
dardization of biliary tract reconstruction. 
The Veno-Venous Bypass 
When liver transplantation was first carried out in dogs, an 
obligatory condition for success was decompression of the vena 
caval and portal venous systems that had to be occluded while the 
native liver was removed and the new organ was sewn in (1,2). In 
the first clinical trials it was found possible to omit this step (s), 
and for a number of years bypasses were not used. Without 
bypasses, the urgency with which the transplantation was per-
formed was comparable to that in the early days of heart surgery 
when open cardiac operations were performed under inflow occlu-
sion. 
In the last three years, pump-driven veno-venous bypass 
techniques without heparin have been developed that have removed 
this urgency and allowed the avoidance of the venous hypertension 
that othetwise is inevitable during the anhepatic phase. The 
advantages include 1) improved intraoperative cardiovascular sta-
bility, 2) preservation of renal function by avoidance of the renal-
venous hypertension, 3) diminished blood loss, 4) reduced trauma 
to the gastrointestinal tract by avoidance of the portal venous 
hypertension, and S) creation of an operating-room ambience 
compatible with training a new generation of surgeons who in 
turn will set up numerous new centers in the United States and 
other countries. 
The veno-venous bypass has changed the technical strategy 
of liver transplantation in important ways. In the past, when time 
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was such a critical factor during the anhepatic phase, it was impos-
sible to obtain meticulous hemostasis in the bare areas opened up 
by removal of the diseased native liver. Even had there been time, 
it was often impossible to clean up and make dry the raw surfaces 
that were exuding blood at a voluminous rate because of venous 
hypertension. Control of bleeding by mechanical means was fre-
quently impossible until the new liver was in place and until the 
obstructed venous beds were decompressed by opening the caval 
and portal venous anastomoses. 
If veno-venous bypass is used, techniques can be applied 
whereby most or all of the bare areas are closed by running 
sutures. Although these maneuvers may require 1 h or longer 
before the anastomoses are started, the investment pays rich 
dividends later in ease of hemostasis. 
Biliary Tract Reconstruction 
Until about eight years ago, biliary tract reconstruction was 
called the Achilles heel of liver transplantation, with failure rates 
as high as 30-50%. At that time, the gallbladder usually was used 
for reconstruction, the pathway of bile excretion being from the 
common duct through the cystic duct and gallbladder and into the 
intestine. Duct-to-duct and duct-to-bowel reconstruction were 
not employed frequently . 
Today, all biliary tract reconstructions are performed by one 
or the other of the techniques shown in Figure 1.3-namely, 
choledochocholedochostomy with aT-tube stent, or choledochoje-
junostomy to a Roux limb of jejunum. With these procedures, 90% 
or more of the biliary tract anastomoses are successful on the first 
occasion, and even when there are complications, they usually are 
easily rectified. 
ORGAN REMOVAL AND PRESERVATION 
Great advances have been made in multiple organ removal, 
and a relatively standard procedure is being used throughout most 
of the United States (12). The operation is done through a complete 
midline incision from the suprasternal notch to the pubis, including 
splitting of the sternum. The principle followed is to dissect the 
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FIGURE 1.3. Completed orthotopic liver transplantation. (A) Biliary 
tract reconstruction with choledochocholedochostomy. (B) Biliary tract 
reconstruction with choledochojejunostomy, using a Roux limb. From 
Hepatology (2: 614-36) @ 1982. By permission of the American Association 
for the Study of Liver Diseases. 
aorta for cross-clamping at a level that will allow intra aortic infusion 
of cold fluids that will pass into the organs to be removed. If the 
liver is to be one of these organs, dissection of the liver hilum is 
carried out, after which the liver can be infused through both the 
aorta and portal vein (Figure 1K4~K The kidneys also are cooled by 
the aortic perfusion. In the example shown in Figure 1.4, the liver 
and both kidneys are to be removed. With minor modifications, 
the heart can also be excised. 
This procurement technique requires "brain death" conditions 
with stable cardiovascular function. An alternative with which we 
have had recent experience can be done swiftly, and in donors who 
have had cardiac arrest (11). With this so-called fast method, a 
cross-clamp is placed on the aorta near the diaphragm and cold 
solutions (usually the high potassium, high magnesium concen-
tration Collin's solution) are infused rapidly. Blood enters the liver 
through the normal celiac axis route but also through the portal 
vein after passing through the splanchnic capillary bed (Figure 
1.5). The portal venous blood quickly becomes almost red-cell free. 
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FIGURE 1.4 In situ infusion technique used when the kidneys and liver 
are removed from the same donor. R.g.a., right gastric artery; G.d.a., 
gastroduodenal artery; S.a., splenic artery; S.v., splenic vein; P.v., portal 
vein, and S.m.v., superior mesenteric vein. From Surg GynecoI Obstet 
158:223-30 (1984). By permission of Surgery, Gynecology, and Obstetrics. 
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FIGURE 1.5. Method of rapid liver cooling that can be done without 
any preliminary dissection except for insertion of a distal aortic cannula 
and cross-clamping of the aorta at the diaphragm. The infusion fluid 
quickly get into the portal system via the splanchnic capillary bed, provid-
ing double inflow cooling. From Transplant Proc 17:250-58 (1985).By per-
mission of Transplantation Proceedings. 
The cold ischemia limit that is permissible for a human liver 
graft has been set arbitrarily at 10 hi but great efforts are made to 
work within a 5- or 6-h time frame. One of the most urgent needs 
in liver transplantation is the development of better methods of 
preservation. Any technique that would allow safe preservation of 
livers for the better part of a day would revolutionize the field 
overnight. 
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TABLE 1.1. Indications for Liver Transplantation in 140 Adults 
indication Numher Percent 
Acute hepatic necrosis 3 2.1% 
Budd-Chiari syndrome 5 3.6% 
Cirrhosis 46 32.9% 
Inborn errors of metabolism 11 7.9% 
Alpha-I-antitrypsin deficiency 6 4.3% 
Wilson's disease 3 2.1% 
TyrOSinemia 1 0.7% 
Primary biliary cirrhosis 36 25.7% 
Primary hepatic tumors 13 9.3% 
Secondary biliary cirrhosis 5 3.6% 
Sclerosing cholangitis 19 13.6% 
Other ~ 2 1.4% 
INDICA TIONS FOR TRANSPLANT A TION AND RESULTS 
The indications for liver replacement in the developmental 
phase of this field have been documented elsewhere (6) and will 
not be mentioned here. Since the beginning of the cyclosporine 
era, 244 patients underwent this procedure between March 1980 
and July 1, 1984. Tables 1.1 and 1.2 show the principal indications 
for these operations. In about 10% of cases, there were multiple 
pathologic diagnoses such as the incidental presence of primary 
hepatic malignancies in livers with a variety of underlying chronic 
diseases. 
'The profile of diseases in pediatric patients (less than 18 years) 
has been different from that in adults. In adults, postnecrotic 
cirrhosis has been the most important reason for proceeding (Table 
1.1). Other common diseases in adults have been primary biliary 
cirrhosis and sclerosing cholangitis. In children, more than half of 
all the transplantations have been done for biliary atresia, the only 
other large group being a heterogeneous collection of inborn errors 
of metabolism (Table 1.2). The inborn errors, if they are hepatic-
based, are cured permanently by liver replacement since the phe-
notype of the new liver remains that of the original donor (5,6, 11). 
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TABLE 1.2. Indications for Liver Transplantation in 104 Children 
Indica/ion Number Peretnt 
Biliary atresia 56 53.8% 
Budd-Chiari syndrome 1 1.0% 
Cirrhosis 10 9.6% 
Familial cholestasis 7 6.7% 
Inborn errors of metabolism 23 22.1 % 
Alpha-I-antitrypsin deficiency 15 14.4% 
Wilson's disease 4 3.8% 
Tyrosinemia 3 2.9% 
Neonatal hepa titis 3 2.9'Yo 
Secondary biliary cirrhosis 1 1.0% 
Sclerosing cholangitis 1 1.0% 
Other • 2 1.6% 
Influence of Age on Survival 
Aside from the fact that the disease profiles leading to trans-
plantation are different in children versus adults, another justifi-
cation for stratification into adult and pediatric categories is the 
influence of age on survival. It was noted in the days of conventional 
immunosuppression that the results were better in pediatric recip-
ients (6). The disparity in results in pediatric versus adult cases has 
been even more striking during the cyclosporine era (6, I I). The 
actuarial5-year survival ~n adults is projected at about 50%, com-
pared with more than 70% for the pediatric recipients. In view of 
the importance of the age factor, it will be important for groups 
reporting results to stipulate age distribution in their series. In our 
own experience using conventional immunosuppression from 1963 
to 1979, half of the recipients were infants, children, and teenagers. 
In the subsequent years using cyclosporine, the pediatric component 
has never been this high (J I). 
With the appropriate age stratification, meaningful compari-
sons become possible between what was achievable in the precy-
closporine era versus now. In adults, the projected 5-year survival 
after liver transplantation, while still unsatisfactory, is nearly 
three times better than it was previously. In children, the divergence 
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of results using conventional immunosuppression compared with 
the present time has been even more striking. 
The Influence of Diseases upon Prognosis 
There are no diseases for which transplantation has been 
carried out in the past that can be automatically precluded from 
future trials. Usually, the nature of the 'Original disease has not 
profoundly influenced the outcome after transplantation. For 
example, the results in adults have been similar with such diverse 
diseases as primary biliary cirrhosis, sclerosing cholangitis, and 
inborn errors of metabolism. Nevertheless, there may be some 
high-risk diseases. So far, the results with postnecrotic cirrhosis 
and primary hepatic tumors have been inferior. With cirrhosis, the 
principal explanations have been the tech'nica\ difficulties of the 
operation caused by the pathologic process, the generally poor 
condition of the cirrhotic patients, and almost universal recapitu-
lation of their original chronic active hepatitis in B-virus carriers. 
In patients whose reason for liver replacement was a primary 
hepatic malignancy that could not be removed by conventional 
subtotal hepatic resection, the early mortality has been quite low, 
with more than 80% of the recipients being alive at 6 months. The 
steady decline thereafter has been caused by recurrent tumors, 
which can be expected in 80% or more of patients who live long 
enough for metastases to be detected. The only acceptable results 
thus far have been in patients with the slow-growing and nonag-
gressive fibroiamellar hepatomas that recently have been recog-
nized to be a favorable variant within the larger hepatoma category 
(6,11). It has been exceptionally disappointing to °note that no 
patient in the world has ever been cured of a duct cell carcinoma by 
liver transplantation. This has been unexpected since the small 
duct cell carcinomas at the confluence of the right and left hepatic 
ducts (Klatskin tumors) were once thought to be an almost ideal 
indication for liver replacement. 
In children, the results have been about the same in all of the 
main disease categories. It was thought once that the technical 
problems in frequently reoperated children with biliary atresia 
would result in an increased mortality. Almost all such infants and 
children have had portoenterostomies, and many have had multiple 
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later surgical interventions in and around the hepatic hilum. 
Although transplantation is technically much more difficult under 
such circumstances, there has been no demonstrable penalty in 
terms of either early or late survival. 
The Role of Retransplantation 
Before the cyclosporine era, retransplantahon in the event of 
failure of the first liver was almost never successful (6). Twenty-one 
patients had retransplantations carried out between 1963 and 
1979 under conventional immunosuppression, with only 4 patients 
living for as long as an additional 6 months. Even these 4 exceptional 
recipients died 6, 12, 13, and 16 months after retransplantation. 
The effectiveness of retransplantation has improved greatly 
since the introduction of cyclosporine, with a subsequent I-year 
survival of almost 50% (6, 13). The success rate for patients whose 
grafts have been in place for some time and failed slowly because 
of rejection has been high. The worst results have been in patients 
with immediate and serious technical complications and those 
whose grafts have undergone a rapid and uncontrolled rejection in 
the first week or two. 
The role of retransplantation in the future has been somewhat 
clouded by the enormous economic ramifications of early technical 
or other complications serious enough to warrant replacement of 
the graft. At the UniverSity of Pittsburgh hospitals, the costs of 
liver replacement averaged less than $100,000 if only one trans-
plantatio'n was performed. In contrast, the bills for patients receiv-
ing multiple grafts (usually two but as many as three) have been 
astronomical and have averaged almost three times as much as for 
patients treated successfully from the beginning. 
Both in adults and in children, but particularly the latter, 
technical complications have played an important role in necessi-
tating attempts at retransplantation (13). The lesson has been 
clear tha t if a perfect operation is not performed the first time for 
any reason, the cost will be prodigious and will have to be borne by 
the patient or, more commonly, the health insurance carrier. In 
future years it will become important to try to identify those 
patients for whom retransplantation offers little or no chance of 
survival, 50 that expensive and ineffective attempts can be avoided 
with some degree of accuracy. 
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SUMMARY 
During the last five years, liver transplantation has become a 
service as opposed to an experimen tal operation. The most impor-
tant factor in making this possible has been the introduction of 
cyclosporine-steroid therapy. At the same time, liver transplanta-
tion has been made more practical by improvements in anesthetic 
and surgical technique, including perfection of intraoperative 
veno-venous bypasses and the standardization of biliary tract 
reconstruction. Tissue typing and matching has played no role in 
improving the results of liver transplantation. With the demon-
stration that preformed antibody states are irrelevant, even avoid-
ance of positive cross-matches caused by cytotoxic antibodies and 
observance of ABO blood-group barriers have become unnecessary 
if the recipient's needs are great. • 
With the exceptions of malignancy and cirrhosis, the nature 
of the underlying hepatic disease has not profoundly influenced 
the results. Retransplantation has played an important role in 
improving survival, although the costs of retransplantation have 
been extremely high. Many aspects of liver transplantation need 
to be improved, including the development of better methods of 
preservation that will allow the recipient operations to be done in a 
more leisurely manner and at more convenient times. 
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